NILIT
18.4.2024 05:31:30 CEST | Business Wire | Press release
NILIT, the global leader in high-performance Nylon 6.6 fibers for the apparel industry and leader in sustainability, that owns the broadest line of sustainable Nylon 6.6 products, is announcing a new joint venture with Shenma Industry Co., Ltd. (hereinafter referred to as Shenma), a subsidiary of China Pingmei Shenma Group, a global leader in the industrial Nylon 6.6 market and a leading supplier to the automotive industry around the world. This new partnership represents a significant expansion of production capacity within China, also demonstrating NILIT’s ongoing commitment to support the growth of global customers and brands. This expansion is highlighted by multiple investments and cooperation designed to enhance production capabilities and deliver more innovative solutions to the textile industry.
“We are pleased to unveil this new greenfield joint venture in China with Shenma to introduce differentiated state-of-the-art technologies to support the local market,” says Ilan Melamed, NILIT Global General Manager. “This collaboration is set to produce premium specialized products in Fully Drawn Yarns (FDY), known for their outstanding strength and smoothness, and Air Textured Yarns (ATY), known for providing unparalleled softness for the textile market, providing quality and performance, all within a highly competitive cost structure. This partnership will open new opportunities in end uses such as home textiles and the automotive industry where strength, smoothness, and durability are essential.” The joint venture will include a new production site in Pingdingshan, the China Nylon City. The facility will be constructed to meet NILIT’s exacting Total Product Sustainability (TPS) standards for environmentally responsible production and is expected to yield a production capacity of 20,000 tons in the next few years.
This strategic partnership brings together the expertise, resources, and networks of NILIT and Shenma, both renowned enterprises in their respective fields. This joint venture combines NILIT's 50 years of global experience in the production and marketing of high-quality Nylon 6.6 yarns for apparel, and Shenma’s leadership excellence in the Chinese market. “With a shared commitment to excellence and innovation, we are poised to leverage our collective strengths to penetrate new markets and amplify our capabilities across China,” continues Ilan Melamed. The joint venture agreement was signed in a ceremony in Shanghai on April 18th attended by leaders from both parties including Mr. Li Mao, Chairman of China Pingmei Shenma Group, and Mr. Michael Levi, Chairman of NILIT Group.
This model of collaboration showcases the mutual benefits of such alliances, including market access, regulatory navigation, and competitive advantage, emphasizing the market leadership of the NILIT team in China led by Shay Kastoriano, NILIT Asia GM, and Shenma as a strong local partner in China.
Furthermore, in response to the increasing demand for NILIT's high-end products and the commitment to innovation and sustainability, NILIT is also accelerating its plans to double the production capacity at NILIT’s existing production site located in Suzhou SIP, where Shenma Industrials will be a minority shareholder. This strategic move is aimed at supporting the growing global market demand for NILIT's products, ensuring customers’ needs for advanced and innovative and sustainable materials are met.
About NILIT
Celebrating 50 years of excellence, NILIT offers the broadest collection of premium sustainable Nylon 6.6 yarns designed to empower the apparel industry’s shift to a more sustainable position. With production plants in 4 continents (North America, South America, EMEA and ASIA), NILIT is dedicated to creating innovative and sustainable solutions to advance the textile industry.
NILIT launched industry-first SENSIL® ByNature made using bio-gas from reclaimed landfill waste. SENSIL® BioCare is enhanced with a special technology proven to help lessen the persistence of textile waste in sea water and in landfills. SENSIL® EcoCare, crafted with recycled Nylon, improves circularity and LCA. SENSIL® WaterCare with embedded color saves up to 100% of the water used in the traditional wet dyeing process. Plus, the complete SENSIL® portfolio of products is manufactured according to NILIT’s Total Product Sustainability criteria. These responsible yarns give designers the beautiful, environmentally considerate performance fabrics they need to create apparel collections that respond to consumer demands.
About Shenma
As a leading enterprise in the global Nylon 6.6 industrial yarn industry, Shenma has a strong Nylon 6.6 raw material base, providing a solid guarantee for its industrial yarn production. Therefore, its outstanding industrial yarn production capacity is well-known. It is a leading supplier in the global automotive industry, winning the trust of many leading automotive brands with its key components such as airbags and tire cords.
Through deep cooperation with these automotive brands, Shenma's reputation has been highlighted internationally. These partnerships demonstrate that Shenma is able to meet the strict quality and safety standards required by top manufacturers such as General Motors, Ford, Toyota, and Volkswagen. These partnership relationships not only highlight Shenma's commitment to the Nylon 6.6 supply chain, but also demonstrate Shenma's deep commitment to partners and customers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240417236937/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
